See more : Barker Minerals Ltd. (BKMNF) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Techne Corporation (TECH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Techne Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ZTE Corporation (ZTCOF) Income Statement Analysis – Financial Results
- Minda Corporation Limited (MINDACORP.NS) Income Statement Analysis – Financial Results
- Zephyr Energy plc (ZPHRF) Income Statement Analysis – Financial Results
- Samrat Pharmachem Limited (SAMRATPH.BO) Income Statement Analysis – Financial Results
- Space Shower Skiyaki Holdings Inc. (4838.T) Income Statement Analysis – Financial Results
Bio-Techne Corporation (TECH)
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | 714.01M | 642.99M | 563.00M | 499.02M | 452.25M | 357.76M | 310.58M | 314.56M | 289.96M | 269.05M | 263.96M | 257.42M | 223.48M | 202.62M | 178.65M | 161.26M | 145.01M | 130.90M | 115.36M | 103.84M | 90.90M | 67.30M | 60.90M | 54.60M | 47.70M | 40.30M | 28.70M | 22.30M | 19.30M | 15.70M | 12.50M |
| Cost of Revenue | 389.34M | 366.89M | 349.10M | 298.18M | 255.50M | 240.52M | 210.85M | 188.46M | 162.36M | 144.97M | 106.35M | 79.47M | 78.76M | 65.03M | 54.46M | 55.49M | 52.89M | 46.67M | 45.72M | 36.81M | 34.89M | 35.40M | 32.51M | 28.42M | 23.33M | 25.00M | 17.80M | 17.00M | 17.10M | 16.80M | 15.20M | 11.80M | 9.60M | 8.90M | 7.30M | 6.10M |
| Gross Profit | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | 473.49M | 432.14M | 374.54M | 336.66M | 307.28M | 251.41M | 231.11M | 235.80M | 224.94M | 214.58M | 208.47M | 204.53M | 176.82M | 156.90M | 141.84M | 126.37M | 109.61M | 98.39M | 86.93M | 80.51M | 65.90M | 49.50M | 43.90M | 37.50M | 30.90M | 25.10M | 16.90M | 12.70M | 10.40M | 8.40M | 6.40M |
| Gross Profit Ratio | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.76% | 78.98% | 79.45% | 79.12% | 77.44% | 79.39% | 78.37% | 75.59% | 75.17% | 75.36% | 77.53% | 72.50% | 73.55% | 72.09% | 68.68% | 64.78% | 62.28% | 58.89% | 56.95% | 53.89% | 53.50% | 51.20% |
| Research & Development | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M | 62.41M | 55.33M | 53.51M | 45.19M | 40.85M | 30.95M | 29.26M | 27.91M | 25.99M | 25.12M | 23.56M | 22.39M | 20.08M | 18.83M | 18.38M | 20.77M | 20.58M | 17.47M | 14.52M | 11.20M | 12.00M | 10.60M | 11.70M | 10.40M | 8.60M | 6.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 396.83M | 352.44M | 339.00M | 289.92M | 240.88M | 236.87M | 240.64M | 153.33M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 25.94M | 33.77M | 35.03M | 19.70M | 27.49M | 0.00 | 45.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 396.83M | 378.38M | 372.77M | 324.95M | 260.58M | 264.36M | 240.64M | 199.24M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 9.20M | 8.70M | 7.60M | 7.70M | 6.60M | 5.60M |
| Other Expenses | 0.00 | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.56M | -3.11M | 7.14M | -1.04M | 830.00K | 693.00K | 0.00 | 960.00K | 960.00K | 1.14M | 1.61M | 1.97M | 1.22M | 1.60M | 1.94M | 8.55M | 8.89M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 11.00M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Operating Expenses | 563.04M | 470.87M | 459.91M | 395.55M | 325.78M | 326.77M | 295.97M | 252.76M | 186.07M | 160.25M | 91.66M | 74.83M | 71.72M | 61.88M | 58.26M | 57.69M | 60.24M | 52.66M | 48.40M | 44.08M | 44.10M | 41.90M | 45.57M | 41.13M | 41.16M | 40.80M | 28.30M | 28.60M | 25.30M | 21.50M | 17.50M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Cost & Expenses | 952.37M | 837.76M | 809.01M | 693.74M | 581.27M | 567.29M | 506.82M | 441.22M | 348.43M | 305.22M | 198.01M | 154.30M | 150.48M | 126.91M | 112.72M | 113.18M | 113.13M | 99.33M | 94.11M | 80.89M | 78.98M | 77.29M | 78.08M | 69.55M | 64.49M | 65.80M | 46.10M | 45.60M | 42.40M | 38.30M | 32.70M | 21.80M | 18.20M | 17.10M | 14.20M | 11.90M |
| Interest Income | 3.32M | 3.41M | 794.00K | 473.00K | 605.00K | 569.00K | 409.00K | 304.00K | 249.00K | 634.00K | 2.68M | 2.65M | 2.64M | 3.75M | 4.38M | 7.63M | 12.19M | 8.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.74M | 11.22M | 11.31M | 13.95M | 19.20M | 21.71M | 10.19M | 7.36M | 1.75M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M | 42.76M | 37.23M | 19.18M | 12.32M | 12.47M | 8.70M | 960.00K | 7.77M | 7.26M | 6.99M | 6.96M | 6.11M | 6.04M | 6.35M | 12.69M | 12.74M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 1.80M | 1.30M | 1.00M | 500.00K | 300.00K | 200.00K |
| EBITDA | 310.37M | 460.57M | 420.12M | 258.47M | 373.91M | 211.89M | 200.60M | 179.36M | 191.99M | 192.93M | 180.57M | 172.98M | 174.66M | 173.68M | 164.58M | 158.55M | 151.55M | 137.01M | 115.46M | 103.87M | 88.31M | 74.07M | 65.51M | 58.54M | 52.00M | 37.00M | 23.50M | 17.60M | 14.10M | 11.10M | 9.40M | 8.20M | 5.10M | 2.70M | 1.80M | 800.00K |
| EBITDA Ratio | 26.78% | 35.73% | 35.97% | 25.49% | 21.31% | 20.55% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 54.18% | 57.59% | 59.86% | 60.04% | 62.96% | 59.90% | 59.84% | 57.52% | 58.79% | 56.19% | 51.16% | 63.41% | 50.75% | 50.07% | 39.71% | 33.14% | 27.75% | 25.09% | 22.85% | 24.32% | 29.97% | 26.01% | 13.47% | 10.83% | 5.60% |
| Operating Income | 206.69M | 298.94M | 296.59M | 149.55M | 74.68M | 125.58M | 136.18M | 121.78M | 150.59M | 147.02M | 159.75M | 158.47M | 166.21M | 163.06M | 156.33M | 150.78M | 144.29M | 124.15M | 108.50M | 97.76M | 82.27M | 67.72M | 52.82M | 45.81M | 39.34M | 25.10M | 21.20M | 15.30M | 12.20M | 9.40M | 7.60M | 6.90M | 4.10M | 2.20M | 1.50M | 600.00K |
| Operating Income Ratio | 17.83% | 26.30% | 26.83% | 16.06% | 10.11% | 17.59% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 51.02% | 52.84% | 56.23% | 58.10% | 57.12% | 56.05% | 55.55% | 53.55% | 54.72% | 51.02% | 46.70% | 40.35% | 39.71% | 37.89% | 27.61% | 31.50% | 25.12% | 22.34% | 19.71% | 18.86% | 24.04% | 18.39% | 11.40% | 9.55% | 4.80% |
| Total Other Income/Expenses | -21.00M | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.62M | -3.11M | 7.14M | 1.64M | 2.19M | -4.01M | 1.93M | 118.00K | 4.58M | 9.54M | 4.78M | 2.66M | 2.12M | 268.00K | 1.84M | -15.08M | 2.00M | 66.98K | 1.00M | 1.20M | 700.00K | 400.00K | 200.00K | -400.00K | -400.00K | -800.00K | 0.00 | -100.00K | 0.00 |
| Income Before Tax | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M | 112.02M | 125.95M | 113.16M | 147.48M | 154.16M | 161.39M | 160.66M | 162.20M | 164.98M | 156.45M | 155.36M | 153.83M | 128.93M | 111.16M | 99.89M | 82.54M | 69.56M | 37.74M | 47.81M | 39.41M | 26.10M | 22.40M | 16.00M | 12.60M | 9.60M | 7.20M | 6.50M | 3.30M | 2.20M | 1.40M | 600.00K |
| Income Before Tax Ratio | 16.02% | 29.79% | 27.26% | 15.92% | 37.43% | 15.69% | 19.59% | 20.10% | 29.55% | 34.09% | 45.11% | 51.73% | 51.56% | 56.90% | 58.15% | 58.86% | 59.76% | 57.69% | 54.86% | 55.91% | 51.19% | 47.97% | 28.83% | 41.44% | 37.96% | 28.71% | 33.28% | 26.27% | 23.08% | 20.13% | 17.87% | 22.65% | 14.80% | 11.40% | 8.92% | 4.80% |
| Income Tax Expense | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M | 15.94M | 602.00K | 35.88M | 43.01M | 46.43M | 50.44M | 48.10M | 49.86M | 52.68M | 46.67M | 50.12M | 50.27M | 43.82M | 37.81M | 33.76M | 29.61M | 24.16M | 10.61M | 13.76M | 12.83M | 9.40M | 7.20M | 5.10M | 4.00M | 2.90M | 2.10M | 2.10M | 1.30M | 600.00K | 400.00K | 200.00K |
| Net Income | 168.11M | 285.26M | 272.05M | 140.41M | 229.30M | 96.07M | 125.35M | 77.29M | 104.48M | 107.74M | 110.95M | 112.56M | 112.33M | 112.30M | 109.78M | 105.24M | 103.56M | 85.11M | 73.35M | 66.13M | 52.93M | 45.40M | 27.13M | 34.05M | 26.58M | 16.70M | 15.20M | 10.90M | 8.60M | 6.70M | 5.10M | 4.40M | 2.00M | 1.60M | 1.00M | 400.00K |
| Net Income Ratio | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.49% | 13.73% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.80% | 39.87% | 40.23% | 38.08% | 36.20% | 37.02% | 32.82% | 31.31% | 20.73% | 29.51% | 25.60% | 18.37% | 22.59% | 17.90% | 15.75% | 14.05% | 12.66% | 15.33% | 8.97% | 8.29% | 6.37% | 3.20% |
| EPS | 1.07 | 1.81 | 1.73 | 0.91 | 1.50 | 0.64 | 0.84 | 0.52 | 0.70 | 0.73 | 0.75 | 0.76 | 0.76 | 0.76 | 0.74 | 0.70 | 0.66 | 0.54 | 0.47 | 0.41 | 0.32 | 0.27 | 0.16 | 0.21 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| EPS Diluted | 1.05 | 1.76 | 1.66 | 0.87 | 1.45 | 0.62 | 0.82 | 0.52 | 0.70 | 0.72 | 0.75 | 0.76 | 0.76 | 0.76 | 0.73 | 0.69 | 0.66 | 0.54 | 0.46 | 0.40 | 0.32 | 0.27 | 0.16 | 0.20 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M | 151.12M | 149.90M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M | 156.56M | 157.62M | 156.20M | 161.44M | 164.18M | 165.48M | 166.03M | 165.75M | 162.50M | 160.94M | 151.62M | 150.34M | 155.54M | 152.35M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
| Weighted Avg Shares Out (Dil) | 160.77M | 161.86M | 164.12M | 161.93M | 157.60M | 155.57M | 152.22M | 150.00M | 149.30M | 148.92M | 148.02M | 147.60M | 148.02M | 148.69M | 149.39M | 151.60M | 156.99M | 158.05M | 158.38M | 163.68M | 166.79M | 168.12M | 170.09M | 170.67M | 168.82M | 165.49M | 156.86M | 155.71M | 155.54M | 153.33M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM
MINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems.
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, July 30, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications...
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / July 29, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead...
BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO
MINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and...
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, July 26, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the...
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / July 25, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead...
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, July 24, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or...
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, July 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications...
ODDITY TECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Oddity Tech and Encourages Investors to Contact the Firm
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Oddity Tech (“Oddity Tech” or the “Company”) (NASDAQ: ODD) in...
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS
MINNEAPOLIS , July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results.
Source: https://incomestatements.info
Category: Stock Reports